Secarna Pharmaceuticals, a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotides (ASO) therapies to address challenging or previously undruggable targets reports that its collaboration partner Evotec SE has reached another program designation within its neuroscience collaboration with Bristol Myers Squibb, triggering a payment of $16 million to Evotec.     The program further adds to a fast-growing pipeline in neurodegeneration that ...